Integrative analysis of whole-transcriptome sequencing reveals a ceRNA regulatory network centered on P4ha1 in liver cirrhosis treated with Pien Tze Huang
DOI:
https://doi.org/10.17179/excli2026-9413Keywords:
Cirrhosis, drug treatment, biomarkers, transcriptomics, Pien Tze HuangAbstract
Liver cirrhosis represents a terminal stage of chronic liver disease with limited pharmacological options. Pien Tze Huang (PTH), a traditional Chinese medicine with established hepatoprotective properties, has shown therapeutic potential in liver fibrosis, yet its molecular mechanisms in cirrhosis remain poorly understood. Here, we investigated the anti-cirrhotic effects of PTH and underlying mechanisms through whole-transcriptome sequencing in a carbon tetrachloride (CCl4)-induced mouse model of cirrhosis. PTH treatment significantly attenuated liver injury and other cirrhotic phenotypes, as evidenced by reduced serum transaminases and improved histological features. Transcriptomic analysis identified 1,518 genes dysregulated in cirrhosis and reversed by PTH treatment, with functional enrichment implicating inflammatory and fibrotic pathways including NF-κB, TNF, and IL-17 signaling. Connectivity Map analysis revealed similarity between PTH-induced transcriptional signatures and those of statins and beta-blockers, drugs currently evaluated in cirrhosis clinical trials. Through integrative construction of competing endogenous RNA (ceRNA) networks, we identified a core regulatory module comprising 6 miRNAs, 8 mRNAs, and 27 circRNAs with reversed expression patterns following PTH treatment. Notably, the liver-specific miR-122-5p exhibited the highest network connectivity, targeting P4ha1, a rate-limiting enzyme in collagen biosynthesis. Human proteome data confirmed liver-enriched expression of P4HA1, which is a validated therapeutic target of Lufironil, a Phase II clinical trial drug for cirrhosis. Our findings suggest that PTH ameliorates cirrhosis through multi-pathway regulation of a P4ha1-centered ceRNA network. Functional validation in hepatocytes confirmed that PTH modulates this network via the miR-122-5p/P4HA1 axis, alleviating injury-induced miR-122-5p downregulation and consequent P4HA1 upregulation. These results provide experimental evidence for a mechanistic basis of PTH's therapeutic application and highlight P4ha1 as a promising biomarker for cirrhosis intervention.
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Yunxiao Lin, Fan Yang, Yingtian Zhang, Xiaoqin Zhang, Xiangyi Li, Zhiliang Chen, Xianglong Zhao, Yongzhi Wang, Hao Wu, Cong Huai, Qiange Xiao, Wei Bao, Minglei Yang, Ruoyu Chen, Zhongyu Cao, Jinhang Zhu, ZeKun Yu, Zexiu Zhang, Shengying Qin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
